Evidence map›Paper›PMID 42074066›Full record

ReviewInternational journal of molecular sciences2026

The Therapeutic Potential of Dihydroartemisinin in Cancer Treatment.

Zhaochuan Hu, Shuai Zhang, Yongqi Shi, Yunlei Song, Dan Miao, Wenhe Xiong, Jiaying Guo, Yumao Jiang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhaochuan HuMinistry of Education, Jiangxi Provincial Key Laboratory of Tissue Engineering, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Scientific Research Center, Gannan Medical University, Ganzhou 341000, China.
Shuai ZhangMinistry of Education, Jiangxi Provincial Key Laboratory of Tissue Engineering, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Scientific Research Center, Gannan Medical University, Ganzhou 341000, China.
Yongqi ShiMinistry of Education, Jiangxi Provincial Key Laboratory of Tissue Engineering, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Scientific Research Center, Gannan Medical University, Ganzhou 341000, China.
Yunlei SongMinistry of Education, Jiangxi Provincial Key Laboratory of Tissue Engineering, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Scientific Research Center, Gannan Medical University, Ganzhou 341000, China.
Dan MiaoMinistry of Education, Jiangxi Provincial Key Laboratory of Tissue Engineering, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Scientific Research Center, Gannan Medical University, Ganzhou 341000, China.
Wenhe XiongMinistry of Education, Jiangxi Provincial Key Laboratory of Tissue Engineering, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Scientific Research Center, Gannan Medical University, Ganzhou 341000, China.
Jiaying GuoMinistry of Education, Jiangxi Provincial Key Laboratory of Tissue Engineering, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Scientific Research Center, Gannan Medical University, Ganzhou 341000, China.
Yumao JiangMinistry of Education, Jiangxi Provincial Key Laboratory of Tissue Engineering, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Scientific Research Center, Gannan Medical University, Ganzhou 341000, China.

Funding

Key R&D Project of Ganzhou Science and Technology Plan Project 2022B-SF8897National Natural Science Foundation of China No. 82260793Science and Technology Research Project of Jiangxi Provincial Department of Education GJJ2201443, GJJ2201456
6 · The paper itself

Abstract

Dihydroartemisinin (DHA), the active metabolite of artemisinin derivatives, is a clinically established antimalarial agent that has recently gained significant attention for its anticancer properties. This review systematically examines the molecular mechanisms underlying DHA's antitumor effects and explores innovative strategies to enhance its bioavailability and therapeutic efficacy. DHA demonstrates substantial potential in combination therapies with conventional clinical agents, with its broad anticancer applications being strongly supported by both preclinical and clinical evidence. Furthermore, this article outlines future research directions, discusses challenges in clinical translation, and summarizes current scientific approaches addressing these limitations. Collectively, this review highlights DHA's promising role in cancer treatment and provides a foundation for developing improved therapeutic strategies.

Indexed as

Antineoplastic AgentsArtemisininsNeoplasmsAnimalsAntimalarialsHumansAntimalarialsAntineoplastic AgentsArtemisininsartenimolcancer therapycombination therapydihydroartemisinindrug delivery systemshybrid compounds

Identifiers

PMID42074066
PMCPMC13116139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.